Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WFDC2-shRNA
- Development stage
- Preclinical
- Lead developer
- Shengjing Hospital
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
WFDC2-shRNA is an experimental short hairpin RNA (shRNA) construct designed to silence the expression of the WAP four-disulfide core domain protein 2 (WFDC2), also known as Human Epididymis Protein 4 (HE4). WFDC2 is a protein that is highly expressed in ovarian cancer and serves as a clinical biomarker and potential therapeutic target. By utilizing the RNA interference (RNAi) pathway, WFDC2-shRNA targets WFDC2 mRNA for degradation, leading to a significant reduction in protein levels. Preclinical studies indicate that knockdown of WFDC2 in ovarian cancer cells can inhibit cell proliferation, promote apoptosis, and restore estrogen sensitivity by upregulating estrogen receptor beta (ERβ). This agent is primarily utilized in laboratory settings to investigate the molecular mechanisms of ovarian cancer progression and potential therapeutic strategies.
- Other names
- HE4-shRNAHE-4-shRNAHE 4-shRNAWAP four-disulfide core domain protein 2 short hairpin RNA
02
Targets
WFDC2
Beyond the preview
Go deeper on WFDC2-shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WFDC2-shRNA.